

ABSTRACT 2020

Semmo N, Müllhaupt B, Rückstuhl L, **Magenta L**, Clerc O, Torgler R., Semela D. **Quality of life measurement using wrist actigraphy in HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving ombitasvir, paritaprevir, and ritonavir tablets and dasabuvir tablets (Viekirax/Exviera; 3D regimen).** Abstract presented at EASL Liver meeting 2019 (10–14 April 2019, Vienna).

Aghemo A, Bourgeois S, Gschwantler M, Sanchez Y, Larsen L, Bondin M, **Magenta L**, Asselah T. **Real-world health care resource utilization and quality of life with G/P treatment: A pooled analysis from post-marketing observational studies.** Abstract presented at EASL Liver meeting 2019 (10–14 April 2019, Vienna).

Terziroli Beretta-Piccoli B., Thompson, R., Foskett, P., **Cerny A.**, Merlo, E., Vergani, D., Rougemont, A., Moix, I., Mieli-Vergani, G. and Morris, M. **A novel large heterozygous ABCB4 deletion is associated with severe cholestatic liver disease.** Abstract accepted at 9a Giornata della Ricerca Clinica della Svizzera Italiana 2019 (15 March 2019, Lugano).

Terziroli Beretta-Piccoli B, Baserga A, **Magenta L**, Balmelli M, Moriggia A, Hagara D, Robatto A, Stalder O, **Cerny A**, De Gottardi A. **Treatment cascade of hepatitis C in a non-university hospital setting in Southern Switzerland.** Abstract accepted at 9a Giornata della Ricerca Clinica della Svizzera Italiana 2019 (15 March 2019, Lugano).

Pareti E, Cioffi G, **Cerny A**, Stirnimann G, Casu S, Sokollik C, Braegger C, Semela D, Mieli-Vergani G, Vergani D, Mertens J, **Terziroli Beretta-Piccoli B.** **Preliminary report on the Swiss Autoimmune Hepatitis Cohort Study.** Abstract accepted as poster presentation at SSAI Annual Congress 2019 (5–6 September 2019, Lugano). Poster accepted as poster to SGG SSG Annual Congress 2019 (12–13 September 2019, Interlaken).

Pareti E, Cioffi G, **Cerny A**, Stirnimann G, Filipowicz M, Mertens J, Semela D, **Baserga A**, Bellentani S, **Terziroli Beretta-Piccoli B.** **Preliminary report on the Swiss Primary Biliary Cholangitis Cohort Study.** Abstract accepted as poster presentation at SSAI Annual Congress 2019 (5–6 September 2019, Lugano). Abstract accepted as poster to SGG SSG Annual Congress 2019 (12–13 September 2019, Interlaken).

Müllhaupt B, Semela D, Ruckstuhl L, **Magenta L**, Clerc O, Torgler R, Negro F, Semmo N. **Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic HCV infection in Switzerland: The MYTHEN Study**. Abstract accepted as oral presentation at SGG SSG Annual Congress 2019 (12–13 September 2019, Interlaken).

Semmo N, Müllhaupt B, Ruckstuhl L, **Magenta L**, Clerc O, Torgler R, Semela D. **Quality of Life measurement using wrist actigraphy in HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving ombitasvir, paritaprevir, and ritonavir tablets and dasabuvir tablets (Viekirax®/Exviera®; 3D regimen): The HEMATITE Study**. Abstract accepted at SGG SSG Annual Congress 2019 (12–13 September 2019, Interlaken).

S. Costantini, C. Taiana, B. Terziroli Beretta-Piccoli, G. Rudel, A. Baserga, D. Hagara, A. Cerny, L. **Magenta**. **Look-back procedure to reach non-compliant and lost to follow-up HBV patients**. Abstract accepted as poster presentation at SGG SSG Annual Congress 2019 (12–13 September 2019, Interlaken).

Montano-Loza AJ, Ebadi M, Hansen BE, Hirschfield G, Mason AL, Milkiewicz P, Janik M, Marschall HU, Parés A, Llovet L, Terrabuio D, Akyildiz M, Liberal R, Kerkar N, Boer YS, Lohse A, Drenth JPH, Floreani A, Czubkowski P, Andrade Bellido RJ, Burra P, Secchi MF, Lytvyak E, Jankowska I, Rodriguez M, Sterneck M, Weiler-Normann C, Schramm C, **Terziroli Beretta-Piccoli B**, Schiano TD, Haydel B, Debray D, Girand M, Lacaille F, Donato MF, Burza MA, Socha P, Pawłowska J, Czubkowski P, Akamatsu N, Tanaka A, Ikegami T, Ueda Y, Vergani D, Heneghan M. **Factors Associated with Recurrence of Autoimmune Hepatitis after Liver Transplantation and Effects on Graft and Patient Survival**. Abstract accepted as poster presentation as “Poster of distinction” at AASLD Liver Meeting 2019 in Boston⁹ (8–12 November 2019, Boston, USA).

Lampertico P, Peck-Radosavljevic M, Bondin M, Mazur W, **Magenta L**, Foucher J, Porcalla A, Crown E, Jalundhwala Y, Zhang Z, Mimidis K, Hazzan R, Marques N, Bourgeois S. **Addressing barriers to hepatitis C virus (HCV) elimination: Real-world outcomes in historically underserved patients with chronic HCV infection treated with glecaprevir/pibrentasvir**. Abstract accepted at AASLD Liver Meeting 2019 in Boston⁹ (8–12 November 2019, Boston, USA and at JFHOD 2020, Paris – France; 26th to 29th of March 2020).

Day E, Habraken N, H Valerio, L Runk, A Lloyd, A Aghemo, O Dawson, J Dillon, K Lacombe, JV Lazarus, RT Marinho, **A Moriggia**, A Øvrehus, J Reimer, H Shah, M Torrens, J Bruneau, J Grebely. **Enhanced self-efficacy for HCV management among people participating in an HCV education program focused on drug and alcohol and primary care settings.** Abstract accepted as poster presentation at 8th International Conference on Hepatitis Care in Substance Users, INHSU 2019 (11 – 13 September 2019, Montréal, Canada).

Pareti E, Cioffi G, **Cerny A**, Stirnimann G, Filipowicz M, Mertens J, Semela D, **Baserga A**, Bellentani S, Mieli-Vergani G, Vergani D, **Terziroli Beretta-Piccoli B.** **Preliminary report on the Swiss Primary Biliary Cholangitis Cohort Study.** Abstract accepted as poster presentation at SSAI Swiss Society for Allergology and Immunology Annual Congress 2019 (5–6 September 2019, Lugano).

Terziroli Beretta-Piccoli B, Di Bartolomeo C., Deleonardi G., **Cerny A.**, Müllhaupt B., Semmo N., Semela D., Moradpour D., Mieli-Vergani G., Vergani D., Muratori L., Swiss Hepatitis C Cohort Study. **The effect on autoimmune liver serology of successful treatment of chronic hepatitis C by direct acting antiviral agents.** Abstract accepted as oral presentation at 9a Giornata della Ricerca Clinica della Svizzera Italiana 2019 (15 March 2019, Lugano).

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapp W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Oliveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. **Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.** Lancet. 2019 Dec 14;394(10215):2184–2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Erratum in: Lancet. 2020 Aug 1;396(10247):312. PMID: 31813633.
